Hormone replacement therapy should not be used as secondary prevention of coronary heart disease.
Barbour
M M
MM
Department of Pharmacy Practice, University of Rhode Island, Kingston 02881, USA.
D000367:Age Factors; D000368:Aged; D001241:Aspirin / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000209:etiology; D003327:Coronary Disease / Q000517:prevention & control*; D015914:Estrogen Replacement Therapy / Q000379:methods; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008525:Medroxyprogesterone / Q000627:therapeutic use*; D008875:Middle Aged; D045167:Progesterone Congeners / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013923:Thromboembolism / Q000209:etiology
D004966:Estrogens, Conjugated (USP); D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D045167:Progesterone Congeners; D008525:Medroxyprogesterone; D001241:Aspirin